Julie Pannequin
Inventor
Stats
- 2 US patents issued
- 10 US Applications filed
- most recent filing
This is official USPTO record data
Details
- 2 US Patents Issued
- 10 US Applications Filed
- 37 Total Citation Count
- May 18, 2022 Most Recent Filing
- Apr 8, 2004 Earliest Filing
Work History
| Patent Owner | Applications Filed | Year |
|---|---|---|
| INSERM (Institut National de la Sante et de la Rec herche Medicale) | 1
| 2007
|
| LES LABORATOIRES SERVIER | 2
2 | 2010
2011 |
| Institut National de la Santé et de la Recherche Médicale (INSERM) | 3
| 2010
|
| UNIVERSITE DE MONTPELLIER 1 | 1
| 2007
|
| CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE | 1
2 2 | 2007
2010 2011 |
| INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) | 1
2 | 2007
2011 |
| BIOREALITES, S.A.S. | 3
2 | 2010
2011 |
| THE UNIVERSITY OF MELBOURNE | 1
| 2004
|
Inventor Addresses
| Address | Duration |
|---|---|
| Paris, FR | Feb 08, 07 - Feb 08, 07 |
| SÈTE, FR | Aug 01, 24 - Aug 01, 24 |
| Sète, FR | Dec 22, 15 - Apr 12, 22 |
| SETE, FR | May 19, 11 - May 19, 11 |
| Sete, FR | Aug 19, 10 - Jan 25, 18 |
Technology Profile
| Technology | Matters | |
|---|---|---|
| A61K: | PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES | 10 |
| A61P: | THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS | 4 |
| C07D: | HETEROCYCLIC COMPOUNDS | 1 |
Patents / Publication
| Patents / Publication # | Year of Publication / Issued | Title | Citations |
|---|---|---|---|
| 2024/0252,658 | 2024 | BIFUNCTIONAL PROTAC-TYPE COMPOUNDS TARGETING PXR, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | 0 |
| 11299542 | 2022 | Monoclonal antibodies to progastrin and their uses | 0 |
| 2020/0002,413 | 2020 | MONOCLONAL ANTIBODIES TO PROGASTRIN AND THEIR USES | 0 |
| 10385126 | 2019 | Monoclonal antibodies to progastrin and their uses | 0 |
| 10385124 | 2019 | Monoclonal antibodies to progastrin and their uses | 0 |
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level.
>
Upgrade to our Level for up to -1 portfolios!.